Comparative bioavailability evaluation of erythromycin base and its salts and esters. I. Erythromycin estolate capsules versus enteric-coated erythromycin base tablets.
A randomized crossover study in 16 healthy volunteers given multiple doses of erythromycin base enteric-coated tablets or erythromycin estolate capsules revealed essentially no difference in the resultant plasma concentration of bioactive erythromycin. This similarity in bioactivity persisted despite the fact that total eryghromycin levels (bioactive erythromycin base plus bioinactive erythromycin propionate) were at least three times higher after administration of the estolate than after administration of the base.
D000328:Adult; D001682:Biological Availability; D002214:Capsules; D004917:Erythromycin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000378:metabolism*; D004918:Erythromycin Estolate / Q000008:administration & dosage / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D011897:Random Allocation; D013608:Tablets, Enteric-Coated; D013997:Time Factors
D002214:Capsules; D013608:Tablets, Enteric-Coated; D004917:Erythromycin; D004918:Erythromycin Estolate